Laurus Labs

Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad. It is involved in the research and development of active pharmaceutical ingredients (API) for anti-retrovirals and hepatitis C drugs. It claims to be the world's largest third party API supplier for anti-retrovirals.[4] The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS,[5][6] and hydroxychloroquine tablets, which are used to treat certain types of malaria.[7]

Laurus Labs
Public company
Traded asNSE: LAURUSLABS
IndustryPharmaceuticals
Founded2005[1]
Headquarters
Hyderabad
,
India
Area served
Global
Key people
Satyanarayana Chava (Founder & CEO)[2][3]
Websitelauruslabs.com

In March 2020, Laurus Labs received USFDA approval to market hydroxychloroquine sulfate tablets. The company announced that it would supply hydroxychloroquine to its US partner Rising Pharma for clinical trials of preventive treatment of COVID-19.[8]

References
  1. "Laurus Labs Ltd". Bloomberg. Retrieved 17 April 2020.
  2. "Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts". Moneycontrol. Retrieved 17 April 2020.
  3. "Laurus Labs: A hot startup in the pharma sector". Forbes India. Retrieved 17 April 2020.
  4. "Laurus Labs eyes bigger play in generic formulations segment". Times of India. Retrieved 17 April 2020.
  5. "Laurus Labs gets USFDA nod for HIV drug". Economic Times Health. Retrieved 17 April 2020.
  6. "Laurus Labs is ready to flood the US with cheap HIV drugs". Livemint. Retrieved 17 April 2020.
  7. "Laurus Labs gets USFDA nod for malaria tablets". The Hindu Business Line. Retrieved 17 April 2020.
  8. "Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US". Moneycontrol. Retrieved 17 April 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.